Dare Bioscience (DARE) and its partner Strategic Science & Technologies said Monday they will submit a protocol and statistical analysis plan to the US Food and Drug Administration in Q1 for a phase 3 study of sildenafil cream, 3.6%, an investigational treatment for female sexual arousal disorder.
The companies said they plan to launch a phase 3 study of the topical drug in mid-2025.
The plan reflects FDA feedback for safety and efficacy, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments